tomotherapy - auslvda · 2011. 2. 15. · oligometastatic disease (up to five localizations)...
TRANSCRIPT
![Page 1: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/1.jpg)
Tomotherapy:
Lucca’s experience in the management
of metastasesU.O. Radioterapia P.O. Campo di Marte, Lucca
![Page 2: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/2.jpg)
Lucca’s technological equipment
![Page 3: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/3.jpg)
Patients selection for Tomotherapy
(July 2010-October 2010)
Curative treatments (17 pts):
• HNC: 4 pts (1 reirradiation)
• Prostate cancer: 5 pts
• Thoracic neoplasms
- thymus: 2pts
- lung: 1pt
- esophagus: 2pts
• Abdomen neoplasms
- pancreas: 1pt
- papilla di vater: 1 pt
- cervico-vaginal local recurrence: 1pt
Palliative treatments (8 pts):
• Oligometastatic disease
- Bone: 7pts
- Lung: 1pt
![Page 4: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/4.jpg)
Oligometastatic disease(up to five localizations)
Physician focus on:
• Suitable patient
• Tumor shape
• Tumor site toward OAR
• Fractionation scheme
• PTV margin
Tomotherapy answers:
• Treatment time
• Dose distribution highly conformed with steep dose gradient
![Page 5: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/5.jpg)
Preliminary study for bone metastases
hypofractionation
• Male 61yrs
• Primary prostate cancer
• Painful bone metastases
• 24Gy single fraction
• 20Gy single fraction
• 10Gy x 3 fr DT 30Gy
![Page 6: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/6.jpg)
•Modulation factor
•Field width 1 cm
•Pitch
Highly conformed dose
distribution even for:
Small target
Extremely irregular shape
24Gy Single fraction
![Page 7: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/7.jpg)
24Gy Single fraction
Slowly Gantry rotation
is not enough to
deliver high dose to
irregular target
keeping steep dose
fall-off
exceeds
54.5%
47.3minutes
![Page 8: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/8.jpg)
20Gy Single fraction
•Modulation factor
•Field width 1cm
•Pitch
Less conformed dose
distribution
23.9
minutes
![Page 9: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/9.jpg)
Choose fractionation
• High dose per fraction
besides 24Gy
not achievable
• Maximum dose per
fraction achievable:
16-18Gy
• technical Tomotherapy limits (table movement, gantry rotation time)
• coarse planning parameters (MF, FW, Pitch) reduce treatment quality
• compromise between ability to paint the dose around target and Tomotherapy mechanism
![Page 10: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/10.jpg)
Lucca experience
on metastases
treated with TomotherapyJuly 2010-October 2010
![Page 11: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/11.jpg)
Fractionation schemes:
• Thorax 5Gy x 6 DT 30Gy: 1pt
• Bones 3Gy x 10 DT 30Gy: 2pts
4Gy x 5 DT 20Gy: 1pt
8Gy single fraction: 1pt
10Gy x 3 DT 30Gy: 3pts
Margins applied to GTV:
• Thorax: 6mm in each direction but 10mm CC
• Pelvis or abdomen: 6mm isotropic expansion
• Bone: 4mm isotropic expansion
• Head & neck: 3mm “isotropic” espansion
Adequate immobilization devices:
• Abdomen compression
• Vacuum cushions
• thermoplastic mask, shoulder fixator
Mean coregistration shifts (mm): Mean Roll correction 0.4°curative and palliative treatments
sitese x y z
thorax 2.1 2.8 3.9
bone 1.8 3.2 3.1
pelvis 2.5 1.8 5.3
abdomen 2.8 5.4 1.8
![Page 12: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/12.jpg)
Site
Mean Shifts (mm)
(x)
Mean Shifts (mm)
(y)
Mean Shifts (mm)
(z)
Pelvi 3,5 1,9 5,4
ORL 1,8 2,1 2,0
Linfomi 1,8 3,1 3,3
Torace 2,1 3,0 3,6
Addome 5,6 3,1 3,6
Mean coregistration shifts
0
1
2
3
4
5
6
Shift medio (x) Shift medio (y) Shift medio (z)
sh
ift
(mm
)ORL
Linfomi
Torace
Addome
Pelvi
![Page 13: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/13.jpg)
Bone target #1
• Male 61yrs
• Primary
prostate
cancer
• Bone met
(L1)
Treatment time: 12minutes
10Gy x 3 DT30Gy
![Page 14: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/14.jpg)
Treatment time: 26 minutes
3Gy x 10 DT30Gy
Two sites one session
Bone target #2
• Male 46yrs
• Multiple
myeloma
• bone
• (C7, D6)
![Page 15: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/15.jpg)
Treatment time: 16 minutes
5Gy x 5 DT 30Gy
• Female 52yrs
• Primary colorectal
cancer
• Lung metastases
Lung metastases
![Page 16: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/16.jpg)
Cranial stereotactic RT
• Male 48 yrs
• Primary lung cancer
• Prior RTWB
• relapse after 26 months
• single metastases
•16Gy single fraction
•Modulation factor
•Field width 1cm
•Pitch
Extremely high conformed
dose distributionTreatment time: 13 minutes
![Page 17: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/17.jpg)
Traditional Sim and Treat Workflow
Immobilize and Scan
patient
Transfer data to
planning systemImport data for
physician to define
fields and/or contour
Planner tries to
quickly develop plan
Physician
returns to
review plan
Transfer plan data
to R&V system
Import and verify
plan data in R&V
system
Import, assign
and register
DRR’s
Radiation
Therapist:
“How much
longer???” Physicist may
check plan
and R& V
System
Bring
patient in
the room
Take X-rays to
verify patient
positionPhysician reviews
verification X-rays
Patient can now be treated!
Patient now waits
to be treated
Setup patient for
treatment
Bring
patient in
the room
![Page 18: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/18.jpg)
StatRT Sim and Treat Workflow
Immobilize and Scan
patient on the
TomoTherapy Hi-Art
System
Bring
patient in
the room
Treat!Contour StructuresPlanner quickly
optimizes planPhysician
approves Plan
Scan, plan, and treat in as little as 30 minutes
![Page 19: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/19.jpg)
STAT RT
A software for rapid intensity-modulated treatment planning,
enabling conformal radiation treatment plans to be
generated on megavoltage computed tomography (MVCT)
scans.
MVCT treatment planning treatment delivery
as CT simulation
STAT RT allow to acquire scans, plan and deliver treatment
in the same session within one hour.
![Page 20: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/20.jpg)
PROs
• High dose conformity and dose gradient with excellent PTV coverage and adequate OAR sparing regardless of complexity
• Simultaneous treatment of multiple target in the same session
• SIB (WB+SRT)
• Re-treatment near critical structures
• Avoidance of junctions (up to 160cm)
CONs
• Treatment time could be
to long even for fit
patients
• Not reliable for dose per
fraction higher than 18Gy
Thake home messages
![Page 21: Tomotherapy - auslvda · 2011. 2. 15. · Oligometastatic disease (up to five localizations) Physician focus on: • Suitable patient • Tumor shape • Tumor site toward OAR •](https://reader033.vdocument.in/reader033/viewer/2022060923/60aee0891ede7569cb39a4b5/html5/thumbnails/21.jpg)
no way is too long for
a man who knows
where he wants
to go…
… and who is very thirsty